Insulet (NASDAQ:PODD) Stock Gets Price Target Increase from UBS Group

Insulet (NASDAQ:PODD) had its price objective upped by stock analysts at UBS Group from $150.00 to $171.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group‘s price objective points to a potential upside of 16.72% from the company’s current price.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. raised their target price on shares of Insulet from $152.00 to $170.00 and gave the stock a “neutral” rating in a report on Thursday. Jefferies Financial Group restated a “buy” rating and set a $200.00 price target on shares of Insulet in a report on Wednesday. Canaccord Genuity Group reduced their price target on shares of Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. TD Cowen reaffirmed a “hold” rating on shares of Insulet in a research note on Wednesday. Finally, Royal Bank Of Canada raised their price objective on shares of Insulet from $160.00 to $180.00 and gave the stock an “outperform” rating in a research note on Thursday. Twelve research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Hold” and a consensus price target of $185.38.

Insulet Price Performance

Shares of PODD traded down $9.61 during trading hours on Thursday, hitting $146.51. 1,567,721 shares of the company were exchanged, compared to its average volume of 1,380,594. The firm has a fifty day simple moving average of $141.97 and a 200-day simple moving average of $176.65. The company has a market capitalization of $10.16 billion, a PE ratio of 23.86, a PEG ratio of 1.21 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet has a one year low of $126.40 and a one year high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The business had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. During the same period in the prior year, the business posted $1.24 earnings per share. Insulet’s revenue was up 19.2% compared to the same quarter last year. As a group, sell-side analysts predict that Insulet will post 6.75 earnings per share for the current year.

Institutional Trading of Insulet

Hedge funds have recently made changes to their positions in the stock. OneDigital Investment Advisors LLC bought a new stake in Insulet during the 2nd quarter valued at approximately $6,741,000. Headlands Technologies LLC boosted its position in shares of Insulet by 2,041.5% in the second quarter. Headlands Technologies LLC now owns 31,930 shares of the medical instruments supplier’s stock valued at $4,861,000 after acquiring an additional 30,439 shares during the period. Amundi boosted its position in shares of Insulet by 13.6% in the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after acquiring an additional 60,929 shares during the period. Man Group plc acquired a new stake in shares of Insulet in the second quarter worth $78,746,000. Finally, SEB Asset Management AB acquired a new stake in shares of Insulet in the first quarter worth $24,700,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.